Engineered Exosomes Carrying miR-588 for Treatment of Triple Negative Breast Cancer Through Remodeling the Immunosuppressive Microenvironment

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Bou Zerdan M, Ghorayeb T, Saliba F, et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers. 2022;14(5):1253. doi:10.3390/cancers14051253
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. doi:10.1186/s13045-022-01341-0
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Khanam J, Sarkar P, Pal TK. A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics. RSC Adv. 2019;9(1):240–254. doi:10.1039/c8ra08924h
   PubMed Web of Science ®Google Scholar
• Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int J Mol Sci. 2020;21:7619. doi:10.3390/ijms21207619
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. Cancers. 2020;12(7):1765. doi:10.3390/cancers12071765
   PubMed Web of Science ®Google Scholar
• Velasco-Velázquez M, Xolalpa W, Pestell RG. The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets. 2014;18(11):1265–1275. doi:10.1517/14728222.2014.949238
   PubMed Web of Science ®Google Scholar
• Mehla K, Singh PK. Metabolic regulation of macrophage polarization in cancer. Trends in Cancer. 2019;5(12):822–834. doi:10.1016/j.trecan.2019.10.007
   PubMed Web of Science ®Google Scholar
• Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL. Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol. 2021;12:643771. doi:10.3389/fimmu.2021.643771
   PubMed Web of Science ®Google Scholar
• Yu-Ju Wu C, Chen C-H, Lin C-Y, et al. CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2. Neuro Oncol. 2020;22:253–266. doi:10.1093/neuonc/noz189
   PubMed Web of Science ®Google Scholar
• Meng L, Liu C, Lü J, et al. Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells. Nat Commun. 2017;8(1):13964. doi:10.1038/ncomms13964
   PubMedGoogle Scholar
• Zhang Z, Huang Q, Yu L, et al. The Role of miRNA in tumor immune escape and miRNA-based therapeutic strategies. Front Immunol. 2021;12:807895. doi:10.3389/fimmu.2021.807895
   PubMedGoogle Scholar
• Chen Y, Zhang J, Gong W, Dai W, Xu X, Xu S. miR-588 is a prognostic marker in gastric cancer. Aging. 2020;13(2):2101–2117. doi:10.18632/aging.202212
   PubMedGoogle Scholar
• Yu M, Zhang X, Li H, Zhang P, Dong W. MicroRNA-588 is downregulated and may have prognostic and functional roles in human breast cancer. Med Sci Monit. 2017;23:5690–5696. doi:10.12659/msm.905126
   PubMed Web of Science ®Google Scholar
• Zhou X, Xu M, Guo Y, et al. MicroRNA-588 regulates invasion, migration and epithelial-mesenchymal transition via targeting EIF5A2 pathway in gastric cancer. Cancer Manag Res. 2018;10:5187–5197. doi:10.2147/CMAR.S176954
   PubMed Web of Science ®Google Scholar
• Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2019;20(5):1836–1852. doi:10.1093/bib/bby054
   PubMed Web of Science ®Google Scholar
• He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics. 2018;8(1):237–255. doi:10.7150/thno.21945
   PubMed Web of Science ®Google Scholar
• Zhu Q, Ling X, Yang Y, et al. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy. Adv Sci. 2019;6:1801899. doi:10.1002/advs.201801899
   Web of Science ®Google Scholar
• MaruYama T, Chen W, Shibata H. TGF-β and Cancer Immunotherapy. Biol Pharm Bull. 2022;45(2):155–161. doi:10.1248/bpb.b21-00966
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi:10.1016/j.immuni.2019.03.024
   PubMed Web of Science ®Google Scholar
• Gratchev A. TGF-β signalling in tumour associated macrophages. Immunobiology. 2017;222(1):75–81. doi:10.1016/j.imbio.2015.11.016
   PubMed Web of Science ®Google Scholar
• Viel S, Marçais A, Guimaraes FS-F, et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal. 2016;9(415):ra19. doi:10.1126/scisignal.aad1884
   PubMed Web of Science ®Google Scholar
• Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20:171. doi:10.1186/s12943-021-01464-x
   PubMed Web of Science ®Google Scholar
• Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8:49. doi:10.1186/s40364-020-00228-x
   PubMed Web of Science ®Google Scholar
• Barile L, Vassalli G. Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63–78. doi:10.1016/j.pharmthera.2017.02.020
   PubMed Web of Science ®Google Scholar
• Yu X, Odenthal M, Fries JWU. Exosomes as miRNA Carriers: formation–Function–Future. Int J Mol Sci. 2016;17:2028. doi:10.3390/ijms17122028
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Q, Zhang X, et al. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J Nanobiotechnology. 2022;20:279. doi:10.1186/s12951-022-01472-z
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22. doi:10.1038/nrc2748
   PubMed Web of Science ®Google Scholar
• Pina A, Kadri M, Arosio D, et al. Multimeric Presentation of RGD peptidomimetics enhances integrin binding and tumor cell uptake. Chemistry. 2020;26:7492–7496. doi:10.1002/chem.202001115
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Roth P. Immunological effects of chemotherapy and radiotherapy against brain tumors. Expert Rev Anticancer Ther. 2016;16:1087–1094. doi:10.1080/14737140.2016.1229600
   PubMed Web of Science ®Google Scholar
• Qiao J, Liu Z, Fu Y-X. Adapting conventional cancer treatment for immunotherapy. J Mol Med. 2016;94:489–495. doi:10.1007/s00109-016-1393-4
   PubMed Web of Science ®Google Scholar
• Adams S, Diéras V, Barrios CH, et al. Patient-reported outcomes from the Phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31:582–589. doi:10.1016/j.annonc.2020.02.003
   PubMed Web of Science ®Google Scholar